Stock market today: S&P 500 hits fresh record close on stronger economic growth
Citius Pharmaceuticals Inc . (NASDAQ:CTXR) stock has reached a new 52-week low, trading at $0.94. This latest price level reflects a significant downturn for the company, which has seen its stock value plummet by an alarming 95.39% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with technical indicators suggesting oversold conditions. Investors have been closely monitoring CTXR as it struggles to regain its footing in a competitive market, with the current price marking the lowest point in the stock's performance within the last year. The steep decline over the year has raised concerns among shareholders and market analysts alike, as they assess the company's strategies and potential for recovery. Despite current challenges, including a current ratio of 0.41 and negative EBITDA of $42.69M, analysts maintain optimistic projections with expectations of profitability this year. InvestingPro subscribers can access 10+ additional key insights about CTXR's financial health and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.